Find out how CTI can support the entire life cycle of your drug development project
Post-marketing trials require flexibility and long-term commitment. CTI has the global infrastructure, site relationships, and health outcomes expertise to execute Phase IV, Registry, and Expanded Access Programs (EAPs) effectively. Additionally, our turnover rate is less than half of the reported industry average allowing us to provide team continuity for long-term Phase IV commitments and EAPs. Our innovative health outcomes team conducts approximately 15 registries per year. One of our strengths is identifying the most time and cost efficient way to collect required data in order to provide usable analyses for our sponsors’ development goals. Our integrated global expertise in health outcomes, health economics, biostatistics, and epidemiology, along with our familiarity with existing public databases make our team the top choice for late phase research.